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Background: Schizophrenia (SZ) is associated with psychotic experiences and cog-
nitive deficits. Therefore, cognitive function is one of the most critical determinants of 
quality of life in this pathology. Resveratrol has been related to neuroprotective action, 
but there are no studies evaluating resveratrol in SZ. The objective of this study was to 
determine the efficacy of resveratrol supplementation on cognition in individuals with SZ.
Methods: This is a 1-month randomized, double-blind, and controlled trial (NCT 
02062190), in which 19 men with diagnosis of SZ, aged 18–65 years, were assigned 
to a resveratrol supplementation group (200  mg) or placebo group (200  mg), with a 
1-month follow-up. Applying a series of cognitive tests assessed neuropsychology 
performance (Hopkins Verbal Learning Test, Stroop Color and Word Test, and Weschler 
Adult Intelligence Scale) and Brief Psychiatric Rating Scale assessed psychopathology 
severity.
results: There were no significant improvement in neuropsychology performance (epi-
sodic memory, working memory, attention and concentration capacity, inhibitory control, 
interference measures, selective attention, and mental flexibility) and psychopathology 
severity after 1 month of resveratrol supplementation (P > 0.05).
conclusion: In conclusion, we have shown that 1 month of a resveratrol supplemen-
tation (200 mg/day) did not improve episodic memory, working memory, attention and 
concentration capacity, inhibitory control, interference measures, selective attention, and 
mental flexibility as compared with placebo in patients with SZ.
Keywords: resveratrol, cognition, schizophrenia, nutritional requirements, nutrients, polyphenols
inTrODUcTiOn
Schizophrenia (SZ) is a severe mental disorder characterized by psychotic experiences, and profound 
disruptions in thinking, affecting language, perception, and the sense of self (1). It is one of the most 
debilitating psychiatric disorders worldwide (2), and it can impair functioning through the loss of an 
acquired capability to earn a livelihood or the disruption of studies (1). Individuals with SZ experience 
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a range of cognitive deficits and associated dysfunctions in the 
neural systems. Deficits of prefrontal and hippocampal systems 
contribute to disturbances in a number of different cognitive 
domains, each making different contributions to the nature and 
severity of cognitive impairments (2). The  cognitive–neural 
system dysfunction may be a key mechanism in the pathway 
to symptom formation in this pathology and thus plays specific 
role in the development-specific types of symptoms of SZ. Some 
cognitive–neural system disturbances may still serve to limit and 
modify overall life function in individuals with SZ, such as the 
capacity to function well in their everyday lives. Potential agents 
for the specific central executive processes impaired in SZ are 
deficits in context processing and conflict detection, and deficits 
in recollection than in familiarity processes. These deficits are fre-
quently associated with disruptions in the function or structural 
integrity of prefrontal cortex, particularly dorsolateral region of 
prefrontal cortex. There is consistent evidence suggesting impair-
ment in three cognitive domains: working memory, executive 
control, and episodic memory. Therefore, cognitive function 
is one of the most critical determinants of quality of life in this 
pathology (2).
Resveratrol is a polyphenol, produced naturally in dietary 
sources including grapevines, pines, berries, legumes, and 
peanuts. It is one of the main agents in the health-promoting 
effects of red wine, and it can be produced by chemical and 
biotechnological synthesis as a nutritional supplement (3–5). 
Resveratrol has been considered the key ingredient responsible 
for the preventive action of red wine since the stilbene displays 
a neuroprotective action in various models of toxicity (3, 4). 
Animal studies have shown that it is able to cross the blood–
brain barrier (3).
Studies have been performed to assess the effects of oral 
resveratrol on cognitive performance in both healthy and 
cognitively impaired patients (6). These studies provide initial 
evidence that resveratrol improves memory performance and 
increases the functional connectivity of the hippocampus in older 
adults (7). There is mounting evidence that resveratrol exerts 
neuroprotective effects on neurodegenerative diseases, such as 
Alzheimer’s, Huntington’s, and Parkinson’s, and that it can protect 
the brain against the damage induced by toxins and disease (4, 
8–10). However, there are no studies evaluating resveratrol in 
SZ. According to this line of evidence, the objective of this study 
was to determine the efficacy of resveratrol supplementation on 
cognition in individuals with SZ.
MaTerials anD MeThODs
This is a randomized, double-blind, and placebo-controlled trial 
of 19 male volunteers, aged 18–65 years, with a diagnosis of SZ 
established by the Structured Clinical Interview for DSM-IV-
Axis I Disorders. Diagnosis of SZ was obtained trough a tree-step 
method following: (1) clinical interview using information from 
patient and relatives. (2) Chart review of data and results from 
routine laboratory exams to check possible clinical differential 
diagnoses. (3) Final discussion with senior clinical researcher 
with more than 20  years of work and research in major psy-
chiatric illnesses, for exclusion of differential diagnosis and/
or comorbidities. Exclusion criteria were mental retardation 
and conditions due to alcohol, drug, clinical, or neurological 
disorders.
The research participants followed a 1-month resveratrol sup-
plementation program, which was covered by the Public Health 
Service at the SZ Program of Hospital de Clinicas de Porto Alegre 
(HCPA), Brazil. All participants had been on a stable dose of 
clozapine (dose range: 100–900 mg) for at least 6 months and pro-
vided signed informed consent. Exclusion criteria were the use of 
other antipsychotic medications or other diagnosis of psychiatric 
disorder. Participants using antidepressant or anticonvulsant 
were not excluded. Since this is a preliminary study, no formal 
sample size calculation was performed.
The subjects were prescribed two dietary supplements a 
day (200  mg of resveratrol or 200  mg of placebo). Resveratrol 
(trans-resveratrol, 98% purified) and placebo (cornstarch) were 
obtained from a compounding pharmacy in Porto Alegre, RS, 
Brazil. The subjects were instructed to take the first supplement 
after the baseline measurements (day 1) and the last supplement 
at the end of 1 month (day 30). All assessments were taken on 
the first and last days (day 1 and day 30) of the 1-month follow-
up. They were also instructed to maintain their usual diet and 
physical activity throughout the study and to abstain from 
foods containing substantial amounts of resveratrol (e.g., wine, 
red grapes, peanuts, and berries). They were also advised not to 
take any other food supplements. The team used two practices 
to monitor and increase the chances of adherence to the study 
protocol: (a) weekly telephone calls during the study period and 
(b) a pill count on the last day (day 30).
A double-blind trial was performed as recorded in the pro-
tocol http://clinicaltrials.gov (registration no.: NCT 02062190). 
The Research Ethics Committee of HCPA approved this research 
study (registration no.: 110553). CONSORT supported the pro-
tocol for this trial.
neuropsychology assessment
Trained psychologists with expertise in psychiatric disorders 
assessed cognitive performance by applying a series of cognitive 
tests which took approximately 40 min altogether.
Hopkins Verbal Learning Test
This test is meant for individuals 16  years old and older. It 
evaluates the episodic memory of verbal content, with late and 
immediate evocation, besides recognition and recall. The test 
includes a 12-word list with semantic value and a list that adds 
another 12 words for late recognition. The tasks include three 
learning trials, one delayed recall trial (20–25 min later), and one 
late recognition trial (11).
Stroop Color and Word Test
This test assesses inhibitory control, interference measures, selec-
tive attention, and mental flexibility (12). It is performed in three 
steps: first, the subjects read a list of color words; then, they name 
the color of sets of letters; and finally, they name the color of the 
ink of conflicting color words. This final task requires the subjects 
to inhibit the urge to read the color word.
TaBle 1 | Baseline clinical parameters of patients in the resveratrol and 
placebo groups.
resveratrol  
(n = 10)
Placebo  
(n = 9)
P valuea
Age (years) 46.40 ± 11.18 41.00 ± 7.87 0.25
Education (in years) 9.90 ± 3.95 10.22 ± 2.10 0.83
Smoking [n (%)] 4 (40) 3 (33) 1.00
Number of cigarette/day 15 (6–20) 30 (20–40) 0.11
Age of onset of the disease (years) 23.90 ± 5.58 26.44 ± 9.67 0.49
Length of illness (years) 22.50 ± 10.00 14.56 ± 7.92 0.07
Clozapine dose (mg/day) 485 ± 213.50 600 ± 180.27 0.23
assessment of symptoms
BPRS total score 10.5 (2–27) 13 (5–21) 0.72
BPRS positive symptoms 0.5 (0–5) 0 (0–9) 0.97
BPRS negative symptoms 2 (0–14) 3 (0–8) 0.97
assessment neuropsychology
WAIS-R
Digits 8.50 (0–13) 7.5 (1–11) 0.76
Letter–number sequences 7.5 (1–12) 6 (4–12) 0.50
Hopkins Verbal Learning Test
HVLT (total of correct responses) 9.9 ± 2.0 11.2 ± 1.3 0.10
HVLT (total of wrong responses) 2 (0–5) 2 (0–12) 0.78
HVLT (free recall trials) 13.9 ± 4.6 15.2 ± 5.7 0.58
HVLT (delayed recall trial) 43.5 ± 23.1 29.0 ± 11.5 0.11
HVLT (delayed recall trial/time) 24.3 ± 5.7 23.3 ± 11.9 0.86
HVLT (late recognition trial) 7.9 ± 1.7 9.7 ± 2.6 0.10
stroop color and Word Test
Stroop (word) 0 (0–7) 0 (0–21) 0.93
Stroop (word–time) 70.1 ± 31.0 58.4 ± 6.6 0.29
Stroop (color) 5 (2–13) 3 (0–8) 0.16
Stroop (color–time) 104.1 ± 16.5 94.6 ± 22.6 0.32
Stroop (word–color) 8 (2–27) 4 (0–13) 0.09
Stroop (word–color–time) 173 (123–285) 117 (0–232) 0.03
BPRS, Brief Psychiatric Rating Scale; WAIS-R, Weschler Adult Intelligence Scale; HVLT, 
Hopkins Verbal Learning Test.
Data are shown as the mean ± SD, median and range, or relative and absolute 
frequency.
aIndependent samples t-test (symmetrical distribution), Fisher’s exact test (categorical 
variables), or Mann–Whitney test (asymmetrical distribution). A two-tailed P-value 
<0.05 was considered significant.
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Weschler Adult Intelligence Scale – Revised
The core objective of the WAIS-R is to provide information that 
can help identify problem-solving difficulties and specific cogni-
tive deficits (13). The following WAIS-R subtests were used.
Digit Span
This subtest involves the oral repetition of numerical sequences in 
the order they are given (16 items) and the repetition of numeri-
cal sequences backwards (14 items), making up 30 points. This 
subtest investigates immediate repetition (working memory) and 
recall skills. The task is suspended after two mistakes within the 
same repetition series.
Letter–Number Sequencing
Combinations of numbers and letters are presented to the sub-
ject, who in turn should remember the numbers in ascending 
order and the letters in alphabetic order. Working memory and 
attention and concentration capacity stand out among the main 
functions evaluated by this subtest. It has been suggested in the 
literature that among the measures that compose the Working 
Memory Index, this subtest is the most sensitive in evaluating 
neuropsychological deficits resulting from damage to the nervous 
system.
The Brief Psychiatric Rating Scale (BPRS) assessed psychopa-
thology severity. BPRS evaluates current symptoms and positive 
and negative dimensions (negative scores refer to the sum of 
BPRS questions 3, 9, 13, and 16, and positive scores refer to the 
sum of BPRS questions 8, 11, 12, and 15) (14).
statistical analysis
Statistical analysis was performed using SPSS 17.0 for Windows. 
The results were represented as the mean ± SD, or median and 
range, or as percentages (%), as indicated. Data were analyzed 
by t-test (symmetrical distribution) or Mann–Whitney test 
(asymmetrical distribution) for continuous variables, whereas 
the Fisher’s exact test was applied for categorical variables. In 
the pre- and post-intervention comparisons, the paired Student’s 
t-test was applied for normally distributed variables, and the 
Wilcoxon test was applied for asymmetrical distribution.
resUlTs
In total, 10 subjects with SZ were included in a resveratrol 
group and 9 subjects with SZ were placed in a placebo group. 
All subjects had been on clozapine for at least 6  months. The 
baseline characteristics of the subject are described in Table 1. 
The resveratrol and placebo groups were similar in terms of 
age, education, smoking, and age of onset of the disease. There 
was a longer length of illness in the resveratrol group, albeit not 
significant (P = 0.07).
The participants initially formed an apparently homogeneous 
population regarding all the assessed parameters. Resveratrol 
group show higher scores in Stroop (word–color–time category) 
than placebo group, which means that resveratrol group pre-
sented worse performance of attention and memory at baseline 
than placebo group.
Differences between the two groups in the assessed neuropsy-
chology parameters surfaced at the end of 1 month of the trial 
are showed in Table 2. BPRS, digits, and letter–number sequence 
were not significantly modified after resveratrol supplementation. 
In HVLT, delayed recall trial was reduced (P = 0.03) in resveratrol 
group showing worst performance in memory. In the placebo 
group, we found a significant increase in free recall trials category 
of HVLT (P = 0.05) showing worst performance in memory. In 
addition, there were no significant side effects.
DiscUssiOn
To our knowledge, this is the first report of a clinical trial with 
resveratrol supplementation and cognition in patients with SZ. 
The cognitive tasks assessed episodic memory, working memory, 
attention and concentration capacity, inhibitory control, interfer-
ence measures, selective attention, and mental flexibility. In the 
TaBle 2 | characteristics of subjects with schizophrenia at baseline and after 1 month of resveratrol supplementation or placebo.
resveratrol Placebo
Day 1 (baseline) Day 30 P valuea Day 1 (baseline) Day 30 P valuea
assessment of symptoms
BPRS total score 10.5 (2.8–21.3) 16 (3–25.3) 0.48 13 (8–18.5) 14 (4–17.5) 0.92
BPRS positive symptoms 0.5 (0–3.3) 0.5 (0–7) 0.25 0 (0–4) 0.5 (0–2.8) 0.48
BPRS negative symptoms 2 (1.5–8) 3 (0–8.3) 0.93 3 (1–6) 6 (1.5–7.8) 0.20
assessment neuropsychology
WAIS-R
Digits 8.5 (0–13) 9 (1–16) 0.17 7.5 (1–11) 8 (2–11) 0.23
Letter–number sequence 7.5 (1–12) 7.5 (3–12) 0.89 6 (4–12) 7 (4–11) 0.29
Hopkins Verbal Learning Test
HVLT (total of correct responses) 9.9 ± 2.0 9.6 ± 1.6 0.71 11.2 ± 1.3 11.1 ± 0.4 1.00
HVLT (total of wrong responses) 2 (0–5) 2 (0–6) 0.86 2 (0–12) 2.5 (0–12) 0.08
HVLT (free recall trials) 13.9 ± 4.6 16.2 ± 4.9 0.13 15.2 ± 5.7 18.5 ± 3.5 0.05
HVLT (delayed recall trial) 43.5 ± 23.1 24.2 ± 9.6 0.03 29.0 ± 11.5 25.3 ± 4.7 0.45
HVLT (delayed recall trial/time) 24.3 ± 5.7 35.0 ± 14.4 0.23 23.3 ± 11.9 38.4 ± 22.9 0.21
HVLT (late recognition trial) 7.9 ± 1.7 7.4 ± 2.1 0.55 9.7 ± 2.6 10.0 ± 1.8 0.61
stroop color and Word Test
Stroop (word) 0 (0–7) 1 (0–9) 0.83 0 (0–21) 0 (0–13) 0.47
Stroop (word–time) 70.1 ± 31.0 68.2 ± 16.6 0.85 58.4 ± 6.6 58.5 ± 9.4 0.68
Stroop (color) 5 (2–13) 3 (1–17) 0.44 3 (0–8) 2.5 (0–16) 0.46
Stroop (color–time) 104.1 ± 16.5 101.0 ± 22.5 0.41 94.6 ± 22.6 100.8 ± 26.2 0.26
Stroop (word–color) 8 (2–27) 8 (0–24) 0.31 4 (0–13) 5 (1–24) 0.39
Stroop (word–color–time) 173 (123–285) 153 (118–313) 0.72 117 (0–232) 152 (93–238) 0.83
Non-adherence (pill returned) – 5 (0–12) – – 9 (2–18) 0.45
BPRS, Brief Psychiatric Rating Scale; WAIS-R, Weschler Adult Intelligence Scale; HVLT, Hopkins Verbal Learning Test.
Data are shown as the mean ± SD or median and range.
aPaired Student’s t-test was applied for normally distributed variables and Wilcoxon test for asymmetrical distribution. A two-tailed P-value <0.05 was considered significant.
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present data, there were not differences in symptoms (BPRS), 
working memory and attention (WAIS-R), inhibitory control, 
interference measures, selective attention, and mental flexibility 
(Stroop) in resveratrol group as compared to placebo group. 
HVLT (delayed recall trial and free recall trials category) showed 
significant differences after resveratrol and placebo supplementa-
tion, respectively, which seems to suggest that both resveratrol 
and placebo group worsened in episodic memory. This result 
probably occurred in both groups as a consequence of the course 
of disease (2).
In the last years, resveratrol has received important attention 
for its anti-tumorigenic, anti-oxidant, and anti-inflammatory 
benefits. Reports of significant life extension in many in  vitro 
and in  vivo studies supporting a role for resveratrol in treat-
ment of chronic diseases and suggest that resveratrol may have 
the potential to make a revolutionary impact on human health. 
Resveratrol has multiple mechanisms of action, such as intrinsic 
anti-oxidant capacity; interaction with a large number of recep-
tors, kinases, and other enzymes that could plausibly make major 
contributions to its biological effects; stimulation of the activities 
of sirtuin-1 and adenosine monophosphate-activated protein 
kinase, both of which influence the regulation of metabolism in 
multiple tissues; and others. The complexity of resveratrol’s effects 
presents a major dare in advance with human studies (15).
The benefits of resveratrol for memory and for prevention of 
neurodegenerative diseases are well documented in laboratory 
animals, but this aspect is only beginning to be explored through 
a number of ongoing human clinical trials (15). Thus, there 
are conflicting results as to the effect of resveratrol in humans, 
with some studies reporting improvements while others find no 
effects (7, 16). Kennedy et al. (6) studied the vasodilatory action 
of resveratrol in a placebo-controlled study involving 22 healthy 
adults and showed that administration of resveratrol (250 and 
500 mg) resulted in dose-dependent increases in cerebral blood 
flow during cognitive task performance that activates the frontal 
cortex. Nevertheless, cognitive functions were not affected. In a 
similar study, Wightman et al. performed a randomized, double-
blind, and placebo-controlled, with 60 healthy adults receiving 
placebo or resveratrol for 28 days. At the end of the study, the 
performance of cognitively demanding tasks did not result in any 
clear improvements in cognitive function. Previous study shows 
that the lack of cognitive effects may be due to low resveratrol bio-
availability and it reduced efficacy in vivo (17). The bioavailability 
of polyphenols is a complex process influenced by several factors 
such as food composition, dietary patterns, and nutritional and 
pathophysiological status of individuals (8).
Interesting, Witte et  al. (7) studied 23 healthy overweight 
older individuals that completed 26 weeks of resveratrol intake 
(200 mg/day) and provided initial evidence that supplementary 
resveratrol improve memory performance. It supports the 
hypothesis that chronic resveratrol ingestion may exert positive 
effects on brain function. Possibly, beneficial effects on brain may 
translate into behavioral improvements after a sufficiently longer 
duration of resveratrol intake.
Since the cognitive–neural system dysfunction may be a key 
mechanism in the pathway to symptom formation in SZ and 
resveratrol supplementation has demonstrated neuroprotective 
action, we hypothesized that resveratrol could improve the 
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symptoms of psychiatric disorders. Unfortunately, current symp-
toms and positive and negative dimensions were not significantly 
modified after resveratrol supplementation in this study.
There are many reasons for resveratrol’s lack of efficacy in 
human studies. First, there is a considerable heterogeneity in 
study quality, design, and polyphenol formula/dosage (16). 
Second, the optimal resveratrol dose, timing, and duration are 
unknown. Third, resveratrol has relatively low bioavailability due 
to its substantial and rapid hepatic metabolism. Another possible 
explanation is the fact that it is the total polyphenols in red wine, 
not resveratrol alone, that generate the beneficial effects of red 
wine (18). And finally, it is difficult to establish good adherence 
to treatment in patients with psychiatric disorders (19).
It is important to point out that this study must be considered 
in light of some limitations: the study used a small sample size, 
specially for outcome measures such as cognitive performance, 
which ideally require a larger sample than the physiological 
measures; a crossover method was not included; and the study 
used a 1-month supplementation period, which could be deemed 
short. This study provides initial results about resveratrol sup-
plementation on cognitive performance, but future long-term 
clinical trials (greater than 6  months) with larger sample sizes 
are needed to consider possible neuroprotective mechanisms of 
resveratrol.
cOnclUsiOn
In conclusion, we have shown that 1 month of a resveratrol sup-
plementation (200 mg/day) did not improve episodic memory, 
working memory, attention and concentration capacity, inhibi-
tory control, interference measures, selective attention, and men-
tal flexibility as compared with placebo in patients with SZ.
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